Skip to content Skip to footer
S&P 500 boosted by J&J vaccine approval - 1st March

S&P 500 boosted by J&J vaccine approval – 1st March

The S&P 500 rose to start the week as it was officially announced that the Johnson & Johnson COVID-19 vaccine was formally approved.

Over the weekend, the FDA had confirmed that the one-shot vaccine from J&J, which has an efficacy of 66% was authorized to be used in the United States.

Markets were buoyed by the news at the opening-bell, as this became the third vaccine to be approved, joining the Pfizer and Moderna iterations.

The benchmark U.S. index, which was mainly in the red to end February, could be set to breach the 4000 point level, should the momentum continue.

As of writing the S&P 500 was up by over 2.4%, with J&J shares trading almost 1% higher.

 U.S. manufacturing reaches 3-year high

Data released today showed that U.S. manufacturing activity had climbed to its highest level in over 3- years.

Figures released by the Institute for Supply Management (ISM) showed that national factory activity rebounded to a reading of 60.8 in February from 58.7 in January.

This rise saw the ISM index hit its highest level since February 2018. Factory orders across the globe also have recently risen, as Germany, France, Italy and Spain all saw an increase in activity.

Many believe the rise in production could be due to pent up demand, or a sign that the pandemic could be nearing an end.

Over 20 million receive COVID-19 vaccine in the U.K.

Reports from the UK today confirmed that close to over 20 million people have now received the first dose of the COVID-19 vaccine.

Britain has undoubtedly been one of the most effective countries in vaccinating its residents, which is why the government believes the end of the pandemic could come in a matter of months.

Prime Minister Boris Johnson last week stated that he hopes all lockdown restrictions will be lifted by June 21st.

The FTSE 100 rallied on today’s news climbing by 1.62% to start the week.

In total, 20.3 million people have received their first dose of a COVID-19 vaccine.

Source: Reuters

Quote of the day – “The goal of a successful trader is to make the best trades. Money is secondary.”

Alexander Elder

Tradeview Ltd. is not a portfolio manager or an investment advisor. This Market Report is for informational purposes only. Any statements made or opinions voiced in this Market Report do not constitute investment advice. The Tradeview Ltd. Market Report does not constitute a solicitation to buy or sell in the financial markets. Although the information contained in the Market Report comes from trusted sources, Tradeview Ltd. is not responsible for guaranteeing the accuracy, timeliness, completeness, or fitness of such sources. Tradeview Ltd. shall not be responsible for and disclaims all liability for any losses which may be suffered from access and use of the contents of the Tradeview Ltd. Market Report. Trading any financial instrument on margin, using leverage or otherwise involves considerable risk. Therefore, before deciding to participate in any style of trading, you should carefully consider your investment objectives, level of experience and risk appetite. Most importantly, do not invest money you cannot afford to lose. Consulting with your investment counselor, attorney, accountant or other professional upon whom you rely for guidance as to the appropriateness of an investment in any style of trading is recommended.

Tradeview Ltd.

Is licensed to carry on securities investment business and is regulated by the Cayman Islands Monetary Authority (CIMA) as a full securities broker-dealer. Tradeview conducts business pursuant to the Cayman Islands Securities Investment Business Law (SIBL) and its activities fall under the direct supervision of the Investments and Securities Division of CIMA.
Headquarters: 5th Floor Anderson Square, 64 Shedden Road, Georgetown, Grand Cayman, Cayman Islands KY1-1002, BWI.

TVM Global Ltd.

Is licensed and regulated by the Labuan Financial Services Authority (FSA) as a Money Broker, registration number LL15870 licensed to facilitate transactions in foreign exchange pursuant to Labuan Financial Services and Securities Act 2010, the Labuan Companies Act 1990 and the Labuan Business Activity Tax Act 1990.
Headquarters: International Business Financial Centre at Office 5, Jamie Business Center I, Unit F10, First Floor, Paragon Labuan, Jalan Mustapha, 87000 Labuan F.T.

Tradeview Europe Ltd.

Is licensed as a Category 2 Investment Service Company and is regulated by the Malta Financial Services Authority (MFSA). The Malta Financial Services Authority (MFSA) is the single regulator for financial services in Malta. MFSA is a fully autonomous public institution and reports to Parliament on an annual basis. The MFSA is a member of the European Banking Authority (EBA), the European Securities and Markets Authority (ESMA) and the International Organization of Securities Commissions (IOSCO) and is a signatory of the Multilateral Memorandum of Understanding with other European regulatory Institutions. Tradeview is authorized to provide financial services across multiple asset classes and is passported in the EU/EEA under MiFID II (EU Markets in Financial Instruments Directive).
Headquarters: 157 Archbishops Street, Valletta VLT Malta 1440.

Tradeview Financial Markets S.A.C.

Is authorized to conduct business pursuant to and in compliance with the General Law of Companies (LGS) promulgated by the government of Peru. Tradeview Financial Markets S.A.C is registered with the National Superintendence of Public Registries (SUNARP), company number 13089531. Tradeview Financial Markets S.A.C provides financial services in selected OTC derivative markets in compliance with all applicable government regulations.
Headquarters: Los Mirtos 239 Urb. San Eugenio, Lince, Lima, Perú.